EUVIMEDEUVIMED entdecken
Crossref

Serological Markers as Predictors of Anti-TNF Response in Children with Crohn’s Disease

Yaara Lisai-Goldstein, Gili Focht, Esther Orlanski-Meyer, Dotan Yogev, Raffi Lev-Tzion, Oren Ledder, Amit Assa, Victor Manuel Navas-López, Robert N Baldassano, Anthony Otley, Dror S Shouval, Anne M Griffiths und 2 weitere

Digestive Diseases and Sciences · 2025

DOI: 10.1007/s10620-024-08732-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2025. Verfasst von Yaara Lisai-Goldstein und 13 weiteren Autor:innen. Beteiligte Einrichtung: Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Eise…. Hauptthemen laut MEDLINE: Crohn Disease, Adalimumab, Tumor Necrosis Factor-alpha, Gastrointestinal Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: AbbVie Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: To advance personalized medicine in pediatric Crohn's disease (CD), we aimed to explore the utility of serological biomarkers in predicting response to anti-tumor necrosis factor (TNF). METHODS: Children with CD were enrolled at initiation of anti-TNF and followed prospectively at 4 and 12 months thereafter, as well as at last follow-up. At baseline, 10 serological markers of the "PROMETHEUS® IBD sgi Diagnostic test" were measured, including pANCA, ASCA IgG and IgA, anti-CBir1, anti-OmpC, anti-A4-Fla2, anti-Fla-X, SAA, ICAM-1 and VCAM-1. The primary outcome was sustained steroid-free remission (SSFR, i.e. clinical remission without steroids at both 4 and 12 months) and the secondary outcome was primary non-response (PNR). RESULTS: Of the 72 included children (mean age, 12.8 ± 3.1 years; median disease duration, 6.4 months [IQR 2.5-17.3]), 42 (58%) were treated with adalimumab and 30 (42%) with infliximab. PNR was noted in 20 (28%) children and failure to achieve SSFR in 36 (50%). The most common positive serological markers were SAA (86%) and ICAM-1 (82%). In univariate analyses, none of the serological markers achieved statistical significance in association with SSFR or with PNR. In multivariable analysis, positivity of ASCA IgG (OR 3.3 [95%CI 0.8-14.4]) and pANCA (OR 5.3 [95%CI 0.9-48]) were the closest to achieving significance in predicting SSFR, with fair predictive performance for the model (AUC 0.67 [95%CI 0.55-0.80]). CONCLUSION: The serological markers tested here have limited utility in predicting response to anti-TNF treatment. Further studies with larger sample sizes are needed to confirm the utility of ASCA IgG and pANCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAdalimumabTumor Necrosis Factor-alphaGastrointestinal AgentsHumansChildFemaleMaleBiomarkersAdolescentProspective StudiesTreatment OutcomeInfliximabPredictive Value of Tests

Stichwörter der Autor:innen

Anti-TNFCrohn diseasePredictorSerology

Substanzen

BiomarkersAdalimumabTumor Necrosis Factor-alphaInfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Eisenberg R&D Authority, P.O. Box 3235, 9103102, Jerusalem, Israel.
  • Pediatric Gastroenterology and Nutrition Unit, Regional University Hospital of Málaga, Málaga, Spain.
  • Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, The Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  • Department of Pediatrics, IWK Health, Dalhousie University, Halifax, NS, Canada.
  • Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Förderung

  • AbbVie Canada

Zitieren

APA

Lisai-Goldstein, Y., Focht, G., Orlanski-Meyer, E., Yogev, D., Lev-Tzion, R., Ledder, O., Assa, A., Navas-López, V. M., Baldassano, R. N., Otley, A., Shouval, D. S., Griffiths, A. M., Turner, D., & Atia, O. (2025). Serological Markers as Predictors of Anti-TNF Response in Children with Crohn’s Disease. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08732-y

Vancouver

Lisai-Goldstein Y, Focht G, Orlanski-Meyer E, Yogev D, Lev-Tzion R, Ledder O, et al. Serological Markers as Predictors of Anti-TNF Response in Children with Crohn’s Disease. Digestive Diseases and Sciences. 2025. doi:10.1007/s10620-024-08732-y

BibTeX
@article{LisaiGoldstein2025,
  author = {Lisai-Goldstein, Yaara and Focht, Gili and Orlanski-Meyer, Esther and Yogev, Dotan and Lev-Tzion, Raffi and Ledder, Oren and Assa, Amit and Navas-López, Victor Manuel and Baldassano, Robert N and Otley, Anthony and Shouval, Dror S and Griffiths, Anne M and Turner, Dan and Atia, Ohad},
  title = {Serological Markers as Predictors of Anti-TNF Response in Children with Crohn’s Disease},
  journal = {Digestive Diseases and Sciences},
  year = {2025},
  doi = {10.1007/s10620-024-08732-y}
}
Kostenlos starten →